Enrollment In OMS302 Phase 3 Clinical Trial Completed
Omeros Announces Completion Of Enrollment In OMS302 Phase 3 Clinical Trial
– Results Expected this Quarter –
SEATTLE, Oct. 3, 2012 /PRNewswire/ — Omeros Corporation (OMER) today announced that the last patient has been enrolled in the Company’s second Phase 3 clinical trial evaluating OMS302 for use during intraocular lens replacement (ILR) surgery. OMS302, one of Omeros’ proprietary PharmacoSurgery™ products, is added to standard irrigation solution used during ILR procedures to maintain intraoperative mydriasis (pupil dilation) and reduce postoperative pain. Maintenance of mydriasis is critical to the safety and surgical ease of the procedure, while intraoperative pupil constriction increases the risk of injury to intraocular structures and can substantially prolong surgical time.
In its first Phase 3 clinical trial, OMS302 demonstrated statistically significant superiority over placebo in maintenance of intraoperative mydriasis (p
Dooper - No sign of life here, yet - but that's the way I like it. These sleeper picks, where nobody is paying attention, are easy game - with two Phase III trials reporting by year-end (with almost certain solid results) and a deep pipeline beyond the two surgery drugs, we will see the Phase III results drive this near $20 when people wake up to it.
I agree, tredleon. Besides OMER's impressive drug pipeline, there's their GPCR unlocking technology that I believe is vastly underappreciated. It's chugging along, opening pathways for drug development for dozens of afflictions, many of which have no current effective therapies. I think $20 will be just the beginning.